Drug Interactions between indinavir and Prograf
This report displays the potential drug interactions for the following 2 drugs:
- indinavir
- Prograf (tacrolimus)
Interactions between your drugs
tacrolimus indinavir
Applies to: Prograf (tacrolimus) and indinavir
ADJUST DOSE: Coadministration with protease inhibitors (PIs) may significantly increase the blood concentrations of tacrolimus. The proposed mechanism is PI inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme responsible for the metabolic clearance of tacrolimus. Enhanced tacrolimus oral bioavailability due to inhibition of intestinal P-glycoprotein (P-gp) efflux transporter may also contribute. There have been numerous reports of tacrolimus interaction with various PI-containing regimens in the medical literature, which necessitated substantial (> 10-fold) reductions or interruptions in tacrolimus dosing.
MANAGEMENT: Tacrolimus dose reduction is recommended if coadministered with protease inhibitors (PIs) that are potent inhibitors of CYP450 3A4. Frequent monitoring of tacrolimus whole blood trough levels should start within 1 to 3 days of concomitant use and continue as needed, adjusting the dose(s) accordingly. Patients should be closely monitored for development of serious adverse effects such as nephrotoxicity, lymphoma and other malignancies, infections, diabetes, neurotoxicity (tremor, paraesthesia, encephalopathy, delirium, coma), hyperkalemia, QT prolongation, myocardial hypertrophy, and hypertension. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
References (35)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- Cakaloglu Y, Tredger JM, Devlin J, Williams R (1994) "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology, 20, p. 309-16
- (2001) "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical
- (2001) "Product Information. Crixivan (indinavir)." Merck & Co., Inc
- (2001) "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc
- (2001) "Product Information. Agenerase (amprenavir)." Glaxo Wellcome
- (2001) "Product Information. Fortovase (saquinavir)." Roche Laboratories
- Jain AK, Venkataramanan R, Shapiro R, et al. (2002) "The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients." Liver Transpl, 8, p. 841-5
- Jain AK, Venkataramanan R, Shapiro R, et al. (2002) "Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients." Transplant Proc, 34, p. 1540-1
- (2003) "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb
- (2003) "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline
- Schonder KS, Shullo MA, Okusanya O (2003) "Tacrolimus and lopinavir/ritonavir interaction in liver transplantation." Ann Pharmacother, 37, p. 1793-6
- Jain AB, Venkataramanan R, Eghtesad B, et al. (2003) "Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients." Liver Transpl, 9, p. 954-60
- (2006) "Product Information. Prezista (darunavir)." Ortho Biotech Inc
- Teicher E, Vincent I, Bonhomme-Faivre L, et al. (2007) "Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study." Clin Pharmacokinet, 46, p. 941-52
- Pea F, Tavio M, Pavan F, et al. (2008) "Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients." Antivir Ther, 13, p. 739-42
- Mertz D, Battegay M, Marzolini C, Mayr M (2009) "Drug-Drug Interaction in a Kidney Transplant Recipient Receiving HIV Salvage Therapy and Tacrolimus." Am J Kidney Dis
- Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V (2009) "Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient." Fundam Clin Pharmacol, 23, p. 423-5
- Tsapepas DS, Webber AB, Aull MJ, Figueiro JM, Saal SD (2011) "Managing the atazanavir-tacrolimus drug interaction in a renal transplant recipient." Am J Health Syst Pharm, 68, p. 138-42
- (2022) "Product Information. Adoport (tacrolimus)." Sandoz Ltd
- (2024) "Product Information. TACrolimus (Sandoz) (TACrolimus)." Sandoz Pty Ltd
- (2023) "Product Information. Prograf (tacrolimus)." Astellas Pharma US, Inc
- (2023) "Product Information. Astagraf XL (tacrolimus)." Astellas Pharma US, Inc
- (2025) "Product Information. Envarsus XR (tacrolimus)." Veloxis Pharmaceuticals
- (2024) "Product Information. Prograf (tacrolimus)." Astellas Pharma Canada Inc
- (2024) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Canada Inc
- (2024) "Product Information. Envarsus PA (tacrolimus)." Endo Operations LTD
- (2024) "Product Information. Dailiport (tacrolimus)." Sandoz Ltd
- (2025) "Product Information. Prograf (tacrolimus)." Astellas Pharma Ltd
- (2025) "Product Information. Envarsus (tacrolimus)." Chiesi Ltd
- (2025) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Ltd
- (2025) "Product Information. Modigraf (tacrolimus)." Astellas Pharma Ltd
- (2024) "Product Information. Advagraf XL (TACrolimus)." Astellas Pharma Australia Pty Ltd
- (2024) "Product Information. proGRAF (TACrolimus)." Astellas Pharma Australia Pty Ltd
- (2024) "Product Information. TACrolimus XR (Sandoz) (TACrolimus)." Sandoz Pty Ltd
Drug and food/lifestyle interactions
tacrolimus food/lifestyle
Applies to: Prograf (tacrolimus)
GENERALLY AVOID: Grapefruit and/or grapefruit juice may increase the plasma concentrations of tacrolimus. The proposed mechanism for the interaction is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. Although clinical data are lacking, this interaction may result in increased risk of serious adverse reactions such as nephro- and neurotoxicity, as well as other adverse effects associated with tacrolimus such as malignancies, infections, diabetes, hyperkalemia, hypertension, and QT prolongation.
GENERALLY AVOID: Alcohol may modify the rate of tacrolimus release from extended release formulations, thereby potentially increasing the risk of serious adverse reactions.
ADJUST DOSING INTERVAL: Coadministration with food decreases the rate and extent of tacrolimus absorption. This effect is greatest after a high-fat meal.
MANAGEMENT: Patients should avoid consumption of food or drink containing grapefruit during treatment with tacrolimus. Concomitant use of tacrolimus, especially extended release formulations, with alcohol should also be avoided. Tacrolimus extended release formulations should be administered on an empty stomach, at least 1 hour before or 2 hours after a meal, and tacrolimus immediate release formulations should be taken consistently every day with or without food.
References (18)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- Hooks MA (1994) "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother, 28, p. 501-11
- (2022) "Product Information. Adoport (tacrolimus)." Sandoz Ltd
- (2024) "Product Information. TACrolimus (Sandoz) (TACrolimus)." Sandoz Pty Ltd
- (2023) "Product Information. Prograf (tacrolimus)." Astellas Pharma US, Inc
- (2023) "Product Information. Astagraf XL (tacrolimus)." Astellas Pharma US, Inc
- (2025) "Product Information. Envarsus XR (tacrolimus)." Veloxis Pharmaceuticals
- (2024) "Product Information. Prograf (tacrolimus)." Astellas Pharma Canada Inc
- (2024) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Canada Inc
- (2024) "Product Information. Envarsus PA (tacrolimus)." Endo Operations LTD
- (2024) "Product Information. Dailiport (tacrolimus)." Sandoz Ltd
- (2025) "Product Information. Prograf (tacrolimus)." Astellas Pharma Ltd
- (2025) "Product Information. Envarsus (tacrolimus)." Chiesi Ltd
- (2025) "Product Information. Advagraf (tacrolimus)." Astellas Pharma Ltd
- (2025) "Product Information. Modigraf (tacrolimus)." Astellas Pharma Ltd
- (2024) "Product Information. Advagraf XL (TACrolimus)." Astellas Pharma Australia Pty Ltd
- (2024) "Product Information. proGRAF (TACrolimus)." Astellas Pharma Australia Pty Ltd
- (2024) "Product Information. TACrolimus XR (Sandoz) (TACrolimus)." Sandoz Pty Ltd
indinavir food/lifestyle
Applies to: indinavir
ADJUST DOSING INTERVAL: According to the manufacturer, coadministration with a meal high in calories, fat, and protein reduces the absorption of indinavir. In ten patients given indinavir in this manner, the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of indinavir decreased by an average of 84% and 77%, respectively. In contrast, grapefruit juice may have only minor effects on the oral bioavailability of indinavir. The manufacturer's package labeling states that administration of a single 400 mg dose of indinavir with 8 oz. of grapefruit juice decreased indinavir AUC by an average of 26%. Likewise, a study consisting of 14 HIV-infected subjects found no uniform nor significant changes in steady-state indinavir AUC during administration with double-strength grapefruit juice compared to water. There was, however, a delay in absorption (Tmax) due to grapefruit juice that is unlikely to be of clinical significance.
MANAGEMENT: To ensure maximal oral absorption, indinavir should be administered without food but with water 1 hour before or 2 hours after a meal. Alternatively, indinavir may be administered with other liquids such as skim milk, juice, coffee, or tea, or with a light meal (e.g., dry toast with jelly, juice, and coffee with skim milk and sugar; corn flakes, skim milk and sugar).
References (3)
- (2001) "Product Information. Crixivan (indinavir)." Merck & Co., Inc
- Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S (1998) "Single-dose pharmacokinetics of indinavir and the effect of food." Antimicrob Agents Chemother, 42, p. 332-8
- Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R (2001) "Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects." J Clin Pharmacol, 41, p. 435-42
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.